TSO3 Inc

TSO3 — Investor Presentation (March 2017)

23 slides from TSO3's investor presentation, March 2017

  1. Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing

    TSX:TOS To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation March 2017

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TO S The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: TSO3 - Our Vision

    TSO3 ‐ Our Vision TSX:TO S To Create and Deliver the New Standard of Care in Sterile Reprocessing™ 3

  4. Slide 4: Company Milestones

    Company Milestones TSX:TO S 2016 2009 ‐ 2014  Shipped 110 STERIZONE® VP4 Sterilizers  Reworked products  Secured significant PO for 2017 shipments  Record revenues & assembly capacity  Introduced STERIZONE®  US$19.3M in cash1 at Dec. 31, 2016 1998 125L+ and VP4 Sterilizers  Extended FDA Claim

  5. Slide 5: Purpose

    Purpose TSX:TO S A Sterile Device for Every Procedure 5

  6. Slide 6: Multiple Large Target Markets

    Multiple Large Target Markets TSX:TO S Existing Low‐Temp Sterilizer Market Now Possible: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Expanded opportunity to terminally sterilize far more of the 55m annual procedures in US4 • Estimated equipment replacement value $4.5

  7. Slide 7: Growing Demand for MIS & Endoscopy Procedures

    Growing Demand for MIS & Endoscopy Procedures TSX:TO S Aging Recovery Bed Minimally Invasive Surgeries Population Time Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries and Endoscopies2 >30 million MIS procedures annually in the U.S.1 85+  Effective 75‐84  Fa

  8. Slide 8: The Science - Patents Pending or Applied For

    The Science – 36 Patents or Pending or Applied For TSX:TO S 8

  9. Slide 9: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TO S FDA‐Cleared ‐ Dual Sterilant, Low Temperature Sterilization System –With Multi‐Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free cycle selection Proprietary Technology automatically adjusts the ste

  10. Slide 10: Chamber Load Capacities

    Chamber Load Capacities TSX:TO S 10

  11. Slide 11: Improving Existing LT Sterilization Practice

    Improving Existing LT Sterilization Practice TSX:TO S Old Technology TSO3 Technology • 20+ year‐old core technology  Next generation industry technology • Single sterilant  Dual Sterilant • Fixed delivery  Dynamic Delivery • Operators must choose from several  Simple Single Cycle Operation opera

  12. Slide 12: GI Endoscopy Market

    GI Endoscopy Market TSX:TO S Greenfield opportunity for Terminal Sterilization – Displacing HLD Potential to terminally sterilize far more of the 55m+ annual endoscopies1 Almost 50% are colonoscopies – none of which are terminally sterilized today1 Endoscopic Procedures in Europe & US1,2 (millions)

  13. Slide 13: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing TSX:TO S Old Technology TSO3 Technology • Typically high level disinfection  Sterilization not high level disinfection • A fundamentally inferior level of certainty  Far higher degree of certainty • Many contaminated scopes  The only FDA‐cleared technology va

  14. Slide 14: The Problem: Endoscopes & Superbugs

    The Problem: Endoscopes & Superbugs TSX:TO S  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic‐resistant bacteria annually – 23,000 die1  CRE is resistant to most available antibiotics ‐ up to 50% of infected patients die2  CRE infections growing and linke

  15. Slide 15: A Call For Action

    A Call For Action TSX:TO S “Despite reprocessing in accordance with US guidelines, viable microbes and biologic debris persisted in clinically used [GI] endoscopes, suggesting current reprocessing guidelines are not sufficient to ensure successful decontamination.” “Residual contamination was detect

  16. Slide 16: The Solution: FDA Clearance of Endoscope Claims

    The Solution: FDA Clearance of Endoscope Claims TSX:TO S FDA has cleared the STERIZONE® VP4 An Industry First: Sterilizer for the sterilization of multi‐ channeled flexible endoscopes (with July 2016: FDA cleared expanded indications for four or fewer channels) having internal lumens of ≥ 1.45 mm in

  17. Slide 17: Commercialization

    Commercialization TSX:TO S  Getinge Infection Control ‐ Exclusive global distributor “The STERIZONE® VP4 Sterilizer  Global sales & service ‐ over 3,000 associates in 36 countries uniquely addresses an unmet global  US$7.5M license fee paid to TSO3 in 2015 need for cost effective, high throughput

  18. Slide 18: 2016 Financial Highlights - USD

    2016 Financial Highlights – USD TSX:TO S Quarterly Revenues  2016 Highlights: (US$ Millions) 2016: Sold total of  Record Revenues of $13.3M (110 units shipped) 110 Sterilizers PO Received for2017  Gross margin1 of 33%, (36% in the 4th Quarter) which indicates equipment margins and growing consuma

  19. Slide 19: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TO S Stock Price (3/20/17) CAD$2.78 Market Cap CAD$256M Cash & ST Investments (mrq) $19.3M 52 Week High‐Low CAD$3.82‐$2.00 Enterprise Value CAD$229M Total Assets (mrq) $27.6M Avg. Daily Vol. (3 mo.) 0.18M Date Founded 1998 Total Deb

  20. Slide 20: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TO S  Razor/Razorblade recurring revenue business model with proprietary captive consumables.  Industry changing technology that is selling now Global Distribution Partner  Dual sterilant  Dynamic Sterilant Delivery SystemTM  Addressing large market opportunities  Tradit

  21. Slide 21: Contact Us

    Contact Us TSX:TO S Investor Relations TSO3 Inc. ‐ Canada Liolios Group, Inc. 2505, avenue Dalton Scott Liolios, President Tel (949) 574‐3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651‐0003 Barry Mire, Vice President info@tso3.com Tel (416) 644‐

  22. Slide 22: Appendix

    Appendix +35.

  23. Slide 23: Regulatory Progression - Endoscopes

    Regulatory Progression ‐ Endoscopes TSX:TO S FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi‐Critical Critic

TSO3 — Investor Presentation (March 2017) on 6ix